Azitra (AZTR) Other Non Operating Income (2022 - 2026)
Azitra (AZTR) posted Other Non Operating Income of -$4624.0 for Q1 2026, up 22.31% on a QoQ basis from -$5952.0 in Q4 2025, and down 12.21% year-over-year from -$5266.9 in Q1 2025.
Azitra (AZTR) Other Non Operating Income (2022 - 2026) Analysis & Trends
Azitra's Other Non Operating Income history runs 5 years deep, the most recent figure standing at -$4624.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 12.21% year-over-year to -$4624.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43892.0 (down 354.89% YoY) and the FY2025 annual result came in at -$43389.0, down 388.99% from the prior year.
- Other Non Operating Income was -$4624.0 for Q1 2026 at Azitra, up from -$5952.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $198234.0 in Q2 2022 and bottomed at -$47542.0 in Q3 2023.
- A 5-year average of $6975.2 and a median of -$2902.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income surged 828.09% — and 2025, when it slumped 443.04%.
- Azitra's Other Non Operating Income stood at $20014.0 in 2022, then tumbled by 102.95% to -$591.0 in 2023, then jumped by 828.09% to $4303.0 in 2024, then plunged by 238.32% to -$5952.0 in 2025, then climbed by 22.31% to -$4624.0 in 2026.
- Business Quant data shows AZTR's Other Non Operating Income at -$4624.0 in Q1 2026, -$5952.0 in Q4 2025, and -$628.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - |
| 3 | BeOne Medicines | 472.98 Bn | 468.19 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.73 Bn | 116.48 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.59 Bn | 62.84 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - |
| 7 | Argenx Se | 54.67 Bn | 49.49 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 37.96 Bn | 34.95 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.08 Bn | 36.08 Bn | - |
| 10 | Azitra | 2.07 Mn | 2.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,624.00 |
| Dec 31, 2025 | -5,952.00 |
| Sep 30, 2025 | -628.00 |
| Jun 30, 2025 | -32,688.00 |
| Mar 31, 2025 | -4,121.00 |
| Dec 31, 2024 | 4,303.00 |
| Sep 30, 2024 | 7,509.00 |
| Jun 30, 2024 | 9,529.00 |
| Mar 31, 2024 | -6,327.00 |
| Dec 31, 2023 | -591.00 |
| Sep 30, 2023 | -47,542.00 |
| Jun 30, 2023 | -1,683.00 |
| Mar 31, 2023 | -4,792.00 |
| Dec 31, 2022 | 20,014.00 |
| Sep 30, 2022 | -19,038.00 |
| Jun 30, 2022 | 198,234.00 |